Pure Global
NCT05868265

A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract

Neoadjuvant Enfortumab Vedotin in High-Grade Urothelial Carcinoma of the Upper Urinary Tract (Including Ureter and Renal Pelvis)
Memorial Sloan Kettering Cancer Center·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Urothelial Carcinoma
Drug/Device/Intervention
Enfortumab Vedotin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Memorial Sloan Kettering Cancer Center
Location
Basking Ridge,Middletown,Montvale,Commack,Harrison,New York,Uniondale, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Jun 02, 2023
End date
May 01, 2025
Enrollment
24 participants
Primary outcome

Proportion of patients who achieve pathologic complete response

Summary

The purpose of this study is to find out whether the study drug, enfortumab vedotin, is an
 effective and safe treatment for people who have urothelial carcinoma of the upper urinary
 tract. Study participants will be people who are not eligible to receive or have chosen not
 to receive the chemotherapy drug cisplatin for treatment of their cancer. In addition, all
 participants will be planning on having standard surgery to remove their tumor.

ICD-10 classifications
Carcinoma in situ: Other and unspecified urinary organsMalignant neoplasm of ureterMalignant neoplasms of urinary tractMalignant neoplasm: Overlapping lesion of urinary organsMalignant neoplasm: Urethra
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05868265
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05868265 through Pure Global AI's free database. This Phase 2 trial is sponsored by Memorial Sloan Kettering Cancer Center and is currently Recruiting. The study focuses on Urothelial Carcinoma. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.